Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

NCT03471078 PHASE3 COMPLETED Results posted

Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer.

Details

Lead sponsor	Sobi, Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	122
Start date	Fri Oct 12 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Jan 31 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Chemotherapy-induced Thrombocytopenia

Interventions

• Avatrombopag
• Placebo Oral Tablet

Countries

Russia, Ukraine, Serbia, Poland, Hungary, China, United States